Noriega IMF, Arias SEA, García LSMC

Idioma: Español
Referencias bibliográficas: 23
Paginas: 196-202
Archivo PDF: 65.03 Kb.

RESUMEN

Existen diferentes alteraciones hipertensivas durante el embarazo, las cuales constituyen las complicaciones más comunes y conllevan una alta morbimortalidad tanto para el feto como para la madre. Es de vital importancia el reconocimiento oportuno de las mismas y el manejo óptimo de cada caso en específico para mejorar la sobrevida fetal y el posparto. Así mismo, es necesario el conocimiento del manejo, ya que se debe de tener en cuenta el potencial efecto adverso en el feto de los diferentes fármacos utilizados en mujeres hipertensas no embarazadas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Baha MS. Treatment of hypertension in pregnant women. NEJM 1996; 335: 257-265

2. Zareian Z. Hypertensive disorders of pregnancy. Int J Gynaecol Obstet 2004; 87: 194-198.

3. Makhseed V, Musini VM, Ahemed MA. Association of fetal gender with pregnancy-induced hypertension and pre-eclampsia. Int J Gynaecol Obstet 1998; 63: 55-56.

4. Cunningham FG, Lindheimer MD. Hypertension in pregnancy. NEJM 1992; 326: 927.

5. Laskowska M, Laskowska K, Oleszczuk J. Angiotensin-converting enzyme activity in pre-eclampsia. Int J Gynaecol Obstet 2002; 77: 33-34.

6. Vigil-De Gracia P, Lasso M, Montufar-Rueda C. Perinatal outcome in women with severe chronic hypertension during the second half of pregnancy. Int J Gynaecol Obstet 2004; 85: 139-144.

7. Vanek M, Sheiner E, Levy A, Mazor M. Chronic hypertension and the risk of adverse pregnancy outcome after superimposed preeclampsia. Int J Gynaecol Obstet 2004; 86: 7-11.

8. Brown CE, Grant NF, Cox K et al. Low dose aspirin. Relationship of angiotensin II pressor responses, circulating eicosanoids, and pregnancy outcome. Am J Obstet Gynecol 1990; 163: 1853.

9. Shotan A, Widerhorn J et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96: 451.

10. Siba BM. Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. Am J Obstet Gynecol 2004; 190: 1520.

11. Helewa ME, Burrows RF et al. Report of the canadian hypertension society consensus conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997; 157: 715.

12. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG practice bulletin # 33. Washington DC 2002.

13. Sibai BM. Pitfalls in diagnosis and management of preeclampsia. Am J Obstes Gynecol 1988; 159: 1.

14. Sibai BM, Mercer B et al. Sever preeclampsia in the second trimester: recurrent risk and long term prognosis. Am J Obstet Gynecol 1991; 165: 1408.

15. Hall DR, Odendaal HJ, Smith M. Is the prophylactic administration of magnesium sulfate in women with preeclampsia indicated prior labor? BJOG 2000; 107: 903.

16. Dekker GA, Sibai BM. Low dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms and clinical trials. Am J Obstet Gynecol 1993; 168: 214.

17. Beaufils M, Uzan S et al. prevention of preeclampsia by early antiplatelet therapy. Lancet 1985; 1: 840.

18. Schubiger G, Flury G, Nussberger J. Enalapril poor pregnancy induced hypertension: acute renal failure in a neonate. Ann Intern Med 1988; 108: 215.

19. National High Blood Pressure Educational Program Working Group report on high blood pressure on pregnancy. Am J Obstet Gynecol 1990; 163: 1691-712.

20. Sibai BM, Akl S, Fairlie F, Moretti M. A protocol for managing severe preeclampsia in the second trimester. Am J Obstet Gynecol 1990; 163: 733-8.

21. Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. BMJ 1985; 290: 17-23.

22. Rosa FW, Bosco LA, Graham CF, Milstien JB, Dreis M, Creamer J. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 1989; 74: 371-4.

23. Lopez-Llera M. Main clinical types and subtypes of eclampsia. Am J Obstet Gynecol 1992; 166: 4-9.